News | June 23, 2026
FDA advisory panel backs Moderna flu vaccine candidate for older adults
The backing comes as influenza remains a persistent public health burden
The backing comes as influenza remains a persistent public health burden
Dengue, a mosquito-borne viral disease, is emerging as a growing public health threat across Africa
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
NEJM study shows strong protection across strains
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The company says the platform offers improved manufacturability and functional advantages
TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
The company plans to submit the vaccine for regulatory review
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
